Medy-Tox Inc (086900) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Medy-Tox Inc stock KRW 73,040, price KRW 64,000, upside +14.1%, quality 60 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range 62,600 KRW – 301,416 KRW · fair‑value band 60,811 KRW – 91,300 KRW · the 64,000 KRW price screens below the 73,040 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 6, 2026.
Follow Medy-Tox in your weekly email
Every Wednesday you see whether Medy-Tox is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Medy-Tox Inc. operates as a biopharmaceutical company in South Korea.
Show moreShow less
It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles.
The company also offers hyaluronic acid filler products comprising Neuramis and Potenfill that are tissue recovering biomaterials.
In addition, it provides various medical devices, such as ComfortDual for tissue coagulation by using high-frequency current; Neurajet Plus to assist injecting other pharmaceuticals; and Carewave for improving erectile dysfunction by using low-intensity shock wave generated from the electromagnetic method.
It also exports its products to approximately 60 countries, including Japan, Brazil, and internationally. Medy-Tox Inc. was founded in 2000 and is headquartered in Cheongju, South Korea.
Stock analysis
Medy-Tox Inc (086900) currently trades at 64,000 KRW, while our model-based Fair Value estimate is 73,040 KRW, implying the stock looks roughly 12% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 70,720 KRW per share, and 9 of the 26 models we run sit above the 64,000 KRW price.
Bear case: the Dividend Discount group reads lowest at 20,487 KRW, and 17 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 60,811 KRW (bear) to 91,300 KRW (bull), the price of 64,000 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Medy-Tox Inc reported revenue of 247B KRW in FY2025 versus 185B KRW in FY2021, a compound +7.5%/yr. Reported net income was 16.6B KRW in FY2025, compounding −35.2%/yr from FY2021.
Key figures
Market cap 421B KRW (≈ $311M) Small · P/E ratio 28.5 · P/S ratio 1.68 · EPS (TTM) 2,221 KRW · Dividend yield 7.5% · Net margin 6.1% · Return on equity 3.6% · Return on assets (EBIT) 7.9% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 35 out of 100 (low confidence).
What moves the price
The share trades about 54% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 14%, 086900 screens cheaper than that median.
Fair Value models
Bear60,811 KRWFair Value 73,040 KRWBull91,300 KRW
Price 64,000 KRW · Upside +14.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.85/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+8.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.9%
Start year 2020 (pandemic). Over 10 years: +10.8% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−16.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−23.9%
Dividend (yield on the price)7.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−23.9% vs −12.0%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−29% → 7%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Price in line with expectations
The price assumes less growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+6.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+6.4%
Yearly sales growth analysts expect, extended to five years.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +4.5% a year for the price and +4.2% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 557 stocks
Beats the industry median on 13/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score60 · Top 25%
Fair Value upside+14.1% · Top 25%
Profitability
Return on equity (12 months)3.6% · Above median
Return on assets2.9% · Above median
Net margin (12 months)6.1% · Above median
Operating margin (12 months)6.9% · Above median
Growth and dividend
Revenue growth (quarter YoY)11.4% · Above median
Dividend yield (12 months)7.5% · Top 25%
Balance sheet
Debt / equity0.04× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Medy-Tox Inc Fair Value". https://www.fairvalue-calculator.com/stock/086900
Frequently asked questions
Is Medy-Tox Inc (086900) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of 73,040 KRW versus a price of 64,000 KRW, about +14% upside (undervalued).
What is the fair value of 086900?
Our model-based fair value for Medy-Tox Inc is 73,040 KRW (as of Nov 6, 2026), built from audited fundamentals. The current price: 64,000 KRW.
What is the quality score of 086900?
Medy-Tox Inc has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medy-Tox Inc (086900)?
Our model-based price target is the fair value of 73,040 KRW (as of Nov 6, 2026) from 26 valuation models. Cautious scenario 60,811 KRW, optimistic scenario 91,300 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Medy-Tox Inc stock forecast for 2026?
Our models put fair value at 73,040 KRW, about +14% upside versus a price of 64,000 KRW (undervalued). Cautious scenario 60,811 KRW, optimistic scenario 91,300 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Medy-Tox Inc (086900)?
Medy-Tox Inc reported trailing-twelve-month revenue of about 251B KRW (latest available figure, as of Nov 6, 2026).
Does Medy-Tox Inc pay a dividend?
Medy-Tox Inc currently shows a dividend yield of 7.50% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Medy-Tox Inc (086900) and when is the ex-dividend date?
Medy-Tox Inc pays a dividend of 4,800 KRW per share a year, a dividend yield of 7.5%. The last ex-dividend date was Oct 28, 2026. A dividend has been paid every year since at least 2010. Free cash flow covers the dividend 0.88 times. Our assessment: Pays more than it earns. The company pays out more in dividends than it earns, and free cash flow clearly does not cover the dividend either. It may need to be cut unless profits recover.
What growth is priced into Medy-Tox Inc (086900)?
For today's price to be fair in a discounted-cash-flow model, Medy-Tox Inc would have to grow free cash flow by +6.6 % per year for five years (discount rate 10.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.9 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of 086900 use?
Our models discount Medy-Tox Inc at 10.2 %: a base by market capitalisation (small), damped by beta 0.39, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Medy-Tox Inc that is +6.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.2 %) and the same formula as our fair value.
How much growth has Medy-Tox Inc (086900) delivered so far?
Over the past 5 years revenue at Medy-Tox Inc grew +11.9 % a year. The price currently implies free-cash-flow growth of +6.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Medy-Tox Inc (086900) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Medy-Tox Inc (+6.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Medy-Tox Inc (086900)?
The free-cash-flow yield on the price is 6.46 %: that much free cash flow Medy-Tox Inc produces per unit of market value. When it exceeds the discount rate of our models (10.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Medy-Tox Inc (086900)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medy-Tox Inc it is 73,040 KRW per share (as of Nov 6, 2026), against a price of 64,000 KRW. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Medy-Tox Inc stock overvalued or undervalued in 2026?
As of Nov 6, 2026, 086900 trades below its calculated fair value: price 64,000 KRW, fair value 73,040 KRW, a gap of about +14% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 086900?
No. The price is what the market pays today (64,000 KRW); the fair value is what the company's own numbers justify (73,040 KRW). For Medy-Tox Inc the two are 9,040 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Medy-Tox Inc worth?
The market values Medy-Tox Inc at about 421B KRW (market capitalisation, as of Nov 6, 2026). Per share that is 64,000 KRW; our models calculate a fair value of 73,040 KRW per share.
What do the bullish and bearish scenarios say about 086900?
Our models span a range for Medy-Tox Inc: cautious scenario 60,811 KRW, base 73,040 KRW, optimistic 91,300 KRW per share (as of Nov 6, 2026, price 64,000 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 086900?
Medy-Tox Inc trades at a price-to-earnings ratio of 28.5 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 73,040 KRW is built from several models across several years. Other multiples: P/B 0.9, P/S 1.7, EV/EBITDA 10.5.
How solid is the balance sheet of Medy-Tox Inc (086900)?
Balance-sheet figures for Medy-Tox Inc (as of Nov 6, 2026): return on equity 3.6%, debt of 0.04 per unit of equity. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is 086900 from its 52-week high?
Medy-Tox Inc trades at 64,000 KRW, about 54% below its 52-week high of 138,600 KRW and 2% above the low of 62,600 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 73,040 KRW is for.
Which stocks are comparable to Medy-Tox Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medy-Tox Inc stock attractive at the current price?
The data as of Nov 6, 2026: price 64,000 KRW, calculated fair value 73,040 KRW (+14%), Quality Score 60/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 086900 calculated?
We run Medy-Tox Inc through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 73,040 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Medy-Tox Inc currently trades 12% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medy-Tox Inc (086900)?
The closing price on Nov 6, 2026 was 64,000 KRW. Our model-based fair value is 73,040 KRW, about +14% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medy-Tox Inc right now?
The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Key figures of Medy-Tox Inc
How large is the market capitalisation of Medy-Tox Inc (086900)?
The market capitalisation of Medy-Tox Inc is 421B KRW (≈ $311M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medy-Tox Inc (086900)?
The price-to-sales ratio of Medy-Tox Inc is 1.68 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Medy-Tox Inc (086900)?
Earnings per share at Medy-Tox Inc are 2,221 KRW (price ÷ EPS = P/E 28.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Medy-Tox Inc (086900)?
The dividend yield of Medy-Tox Inc is 7.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Medy-Tox Inc (086900)?
The net margin of Medy-Tox Inc is 6.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Medy-Tox Inc (086900)?
The return on equity (ROE) of Medy-Tox Inc is 3.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medy-Tox Inc (086900)?
On an EBIT basis the return on assets of Medy-Tox Inc is 7.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medy-Tox Inc (086900)?
The operating margin of Medy-Tox Inc is 6.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medy-Tox Inc (086900)?
Revenue at Medy-Tox Inc is growing +11.4% versus a year earlier (3y avg +8.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Medy-Tox Inc (086900)?
Earnings per share at Medy-Tox Inc are growing −64.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Medy-Tox Inc (086900) carry?
The net debt of Medy-Tox Inc is 25.7B KRW (fiscal year 2025, ≈ 0.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Medy-Tox Inc in the live analysis
One click puts Medy-Tox Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 6, 2026